QuidelOrtho Corporation (LON:0A55)
| Market Cap | 1.47B |
| Revenue (ttm) | 2.02B |
| Net Income (ttm) | -879.54M |
| Shares Out | n/a |
| EPS (ttm) | -13.01 |
| PE Ratio | n/a |
| Forward PE | 13.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Average Volume | 177 |
| Open | 43.09 |
| Previous Close | 43.64 |
| Day's Range | 43.09 - 43.50 |
| 52-Week Range | 29.91 - 69.67 |
| Beta | n/a |
| RSI | 49.59 |
| Earnings Date | Feb 12, 2026 |
About QuidelOrtho
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]
Financial Performance
In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.
Financial numbers in USD Financial StatementsNews
Innovating Diagnostics and What's Next
SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Sieg...
Insider Buying: Ann Rhoads Acquires Shares of QuidelOrtho Corp (QDEL)
Insider Buying: Ann Rhoads Acquires Shares of QuidelOrtho Corp (QDEL)
Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs
New York City-based Newtyn Management bought 994,332 shares of QuidelOrtho Corporation in the third quarter, increasing its position by an estimated $30.4 million. At quarter-end, the firm reported ho...
QuidelOrtho Corp at Citi Global Healthcare Conference Transcript
QuidelOrtho Corp at Citi Global Healthcare Conference Transcript
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
QuidelOrtho Corporation (QDEL) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:00 PM ESTCompany ParticipantsJoseph Busky - Chief Financial...
Monday 11/24 Insider Buying Report: QDEL, MTCH
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
QuidelOrtho To Participate In Upcoming Investor Conferences
SAN DIEGO , Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team will part...
The Power of Prevention: Detecting Diabetes Before It Strikes
SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD...
Oversold Conditions For QuidelOrtho (QDEL)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand
QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.
QuidelOrtho (QDEL) Reports Strong Q3 Results with 25% EBITDA Margin
QuidelOrtho (QDEL) Reports Strong Q3 Results with 25% EBITDA Margin
QuidelOrtho narrows 2025 revenue guidance to $2.68B–$2.74B as margin initiatives deliver $140M in cost savings
QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript
QuidelOrtho Corporation ( QDEL) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Juliet Cunningham - Vice President of Investor Relations Brian Blaser - President, CEO & Direct...
QuidelOrtho Corp (QDEL) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines with ...
QuidelOrtho Corp (QDEL) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines with Strategic Growth Initiatives
QDEL: Projected FY25 EBITDA Margin at 22%
QDEL: Projected FY25 EBITDA Margin at 22%
QuidelOrtho (QDEL) Q3 2025 Earnings Transcript
QuidelOrtho (QDEL) Q3 2025 Earnings Transcript
QDEL Experiences Adjustments Amid Financial Projections
QDEL Experiences Adjustments Amid Financial Projections
QuidelOrtho (QDEL) Eyes Growth Beyond U.S. Borders
QuidelOrtho (QDEL) Eyes Growth Beyond U.S. Borders
QuidelOrtho Corp Reports Q3 2025 Earnings: Revenue at $700M Beats Estimates, Adjusted EPS at $0. ...
QuidelOrtho Corp Reports Q3 2025 Earnings: Revenue at $700M Beats Estimates, Adjusted EPS at $0.80 Surpasses Expectations
QuidelOrtho (QDEL) Projects FY25 Revenue Between $2.68B and $2.74B
QuidelOrtho (QDEL) Projects FY25 Revenue Between $2.68B and $2.74B
QuidelOrtho (QDEL) Exceeds Q3 Revenue Expectations, Advances Strategic Goals
QuidelOrtho (QDEL) Exceeds Q3 Revenue Expectations, Advances Strategic Goals
QuidelOrtho Reports Third Quarter 2025 Financial Results
― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinanci...
QuidelOrtho Corporation Q3 25 Earnings Conference Call At 5:00 PM ET
(RTTNews) - QuidelOrtho Corporation (QDEL) will host a conference call at 5:00 PM ET on November 5, 2025, to discuss Q3 25 earnings results.
QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay
Clearance expands menu and enables high-sensitivity troponin I measurement to aid in the diagnosis of myocardial infarction SAN DIEGO , Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administrati...
Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics
SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wiersc...